Drug Trial Radar · NCT04852705
A Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Adults Aged 18 Years and Older (COVID-19)
Last checked: Nov 20, 2026Latest source record: Apr 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
28,000
Planned (sponsor's estimate)
Start
May 2021
Primary completion
Nov 2021
Study completion Nov 2022
Sponsor
- Lead sponsor
- Shenzhen Kangtai Biological Products Co., LTDIndustry
- Sponsor type
- Industry
- Collaborators
- Beijing Minhai Biotechnology Co., Ltd
- First posted
- Apr 21, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study will be a multi-national, endpoint-driven, randomized, double-blind, placebo-controlled, adaptive study in which participating adults will be randomized 1:1 to receive 2 doses of either candidate vaccine or placebo on Day 0 and 28. A total of 28,000 healthy adults aged 18 years and older will be enrolled and followed for efficacy, safety, and immunogenicity evaluations.
Conditions
- COVID-19
Interventions
SARS-CoV-2 Vaccine (Vero Cells), InactivatedBiological
2 doses of SARS-CoV-2 Vaccine (Vero Cells), Inactivated should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
PlaceboBiological
2 doses of Placebo should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence density of symptomatic COVID-19 casesTime frame: 14 days after full vaccination
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.